Zobrazeno 1 - 10
of 616
pro vyhledávání: '"Joo-Hang Kim"'
Autor:
Ji-Youn Han, Myung-Ju Ahn, Ki Hyeong Lee, Yun-Gyoo Lee, Dong-Wan Kim, Young Joo Min, Sang-We Kim, Eun Kyung Cho, Joo-Hang Kim, Gyeong-Won Lee, Sung Sook Lee, Na Mi Lee, Hyun Woo Jang, Heewon Han, Hyejoo Park, Jieon Lee, Byoung Chul Cho
Publikováno v:
BMC Medicine, Vol 22, Iss 1, Pp 1-10 (2024)
Abstract Background Lazertinib is a potent, irreversible, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) with significant efficacy in patients with EGFR T790M-mutated non-small cell lung cancer (NSCLC). This
Externí odkaz:
https://doaj.org/article/8bfcc4d65fa047f3a5990e84062ee6df
Autor:
Jiyun Lee, Hee Kyung Ahn, Sang‐We Kim, Ji‐Youn Han, Sung Sook Lee, Hyung Soon Park, Hyun Woo Lee, Joo‐Hang Kim, Eunhan Cho, Reto Huggenberger, Byoung Chul Cho
Publikováno v:
Cancer Medicine, Vol 13, Iss 7, Pp n/a-n/a (2024)
Abstract Objective KINDLE‐Korea is part of a real‐world KINDLE study that aimed to characterize the treatment patterns and clinical outcomes of patients with stage III non‐small cell lung cancer (NSCLC). Materials and Methods The KINDLE was an
Externí odkaz:
https://doaj.org/article/363f3894d7f34432b590291acb09d17c
Autor:
Keunchil Park, Jin-Soo Kim, Joo-Hang Kim, Young-Chul Kim, Hoon-Gu Kim, Eun Kyung Cho, Jong-Youl Jin, Miyoung Kim, Angela Märten, Jin-Hyoung Kang
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-11 (2021)
Abstract Background Afatinib is approved globally for EGFR-TKI treatment-naïve patients with EGFR mutation-positive non-small cell lung cancer (NSCLC). In this Korean expanded access program, we evaluated its ‘real-world’ safety and efficacy. Me
Externí odkaz:
https://doaj.org/article/5eec3f88da44408eabe8ce0a99337a67
Autor:
Yun Beom Sang, Joo-Hang Kim, Chang-Gon Kim, Min Hee Hong, Hye Ryun Kim, Byoung Chul Cho, Sun Min Lim
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
AXL, along with MER and TYRO3, is a receptor tyrosine kinase from the TAM family. Although AXL itself is not thought to be a potent oncogenic driver, overexpression of AXL is known to trigger tumor cell growth, survival, invasion, metastasis, angioge
Externí odkaz:
https://doaj.org/article/f5d17a5e34b34ab981c3f74270569ed3
Autor:
Gyeong‐Won Lee, Se‐Il Go, Dong‐Wan Kim, Hoon‐Gu Kim, Joo‐Hang Kim, Ho Jung An, Joung Soon Jang, Bong‐Seog Kim, Seokyung Hahn, Dae Seog Heo
Publikováno v:
Thoracic Cancer, Vol 11, Iss 1, Pp 62-71 (2020)
Background Clinical impact of the Geriatric Nutritional Risk Index (GNRI) in patients with extensive‐stage disease small cell lung cancer (ED‐SCLC) have not previously been reported. Methods This study analyzed 352 patients enrolled in a previous
Externí odkaz:
https://doaj.org/article/ca7394c18f2a454aad37585d966601d6
Autor:
Ki Hyeong Lee, Byoung Chul Cho, Myung-Ju Ahn, Yun-Gyoo Lee, Youngjoo Lee, Jong-Seok Lee, Joo-Hang Kim, Young Joo Min, Gyeong-Won Lee, Sung Sook Lee, Kyung-Hee Lee, Yoon Ho Ko, Byoung Yong Shim, Sang-We Kim, Sang Won Shin, Jin-Hyuk Choi, Dong-Wan Kim, Eun Kyung Cho, Keon Uk Park, Jin-Soo Kim
Publikováno v:
Cancer Research & Treatment; Jan2024, Vol. 56 Issue 1, p48-60, 13p
Publikováno v:
Annals of Coloproctology, Vol 37, Iss Suppl 1, Pp S39-S43 (2021)
With the advent of checkpoint inhibitors, it has opened up opportunities for numerous cancer patients. However, as is the case with every treatment, complications need to be weighed. Gastrointestinal adverse effects, such as diarrhea and colitis are
Externí odkaz:
https://doaj.org/article/bf924107dc5b4e60aa021dd19273dce8
Publikováno v:
Frontiers in Immunology, Vol 12 (2021)
Non-small-cell lung cancers (NSCLCs) are largely classified into lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC), which have different therapeutic options according to its molecular profiles and immune checkpoint expression, especi
Externí odkaz:
https://doaj.org/article/8f8174824aca43d9b75cf97183d34230
Autor:
Hyun Ae, Jung, Miso, Kim, Hae Su, Kim, Joo-Hang, Kim, Yoon Hee, Choi, Jinhyun, Cho, Ji Hyun, Park, Keon Uk, Park, Bo Mi, Ku, Sehhoon, Park, Jong-Mu, Sun, Se-Hoon, Lee, Jin Seok, Ahn, Keunchil, Park, Myung-Ju, Ahn
Publikováno v:
Journal of Thoracic Oncology. 18:223-231
Thymic epithelial tumors (TETs) are rare but are the most common tumors of the anterior mediastinum. Platinum-based combination chemotherapy is the standard of care for such tumors and is associated with a 50% to 90% objective response rate (ORR) in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::397885255b1248e14df536020bf9b66e
https://doi.org/10.1016/j.jtho.2022.10.008
https://doi.org/10.1016/j.jtho.2022.10.008
Autor:
Bo Mi Ku, Mi Hwa Heo, Joo-Hang Kim, Byoung Chul Cho, Eun Kyung Cho, Young Joo Min, Ki Hyeong Lee, Jong-Mu Sun, Se-Hoon Lee, Jin Seok Ahn, Keunchil Park, Tae Jung Kim, Ho Yun Lee, Hojoong Kim, Kyung-Jong Lee, Myung-Ju Ahn
Publikováno v:
Journal of Pathology and Translational Medicine, Vol 52, Iss 3, Pp 148-156 (2018)
Background Non-small cell lung cancer (NSCLC) is a common type of cancer with poor prognosis. As individual cancers exhibit unique mutation patterns, identifying and characterizing gene mutations in NSCLC might help predict patient outcomes and guide
Externí odkaz:
https://doaj.org/article/7a66a635f60547f5813d1c8d020a6733